Table 2.

Overview of AEs in the safety population

AE, n (%)All patients (N = 60)
Any-grade AEs60 (100.0)
Grade ≥3 AEs30 (50.0)
Grade 5 AEs4 (6.7)
Serious AEs19 (31.7)
AEs leading to taselisib dose modifications
 AE leading to taselisib dose reduction14 (23.3)
 AE leading to taselisib dose interruption27 (45.0)
 AE leading to taselisib discontinuation12 (20.0)